
Zusammenfassung
Bis zu 50 % der Patienten mit chronischen Erkrankungen
nehmen ihre Medikation nicht oder unregelmäßig
ein. Eine geringe Einnahmetreue ist mit einer erhöhten
Morbidität und Mortalität assoziiert.
Es wurde eine selektive Literatursuche mit den deutschen und
englischen Begriffen für Einnahmetreue, Therapietreue,
Compliance, Persistenz, Adhärenz, Konkordanz, Pharmazeutische
Betreuung und Medikationsmanagement durchgeführt.
Hinweise für eine Verbesserung der Einnahmetreue liegen
für folgende Prinzipien vor: individuelle Beratung des
Patienten und der versorgenden Personen, Medikationsmanagement mit Vereinfachung
des Einnahmeschemas und Einsatz von Fixkombinationen sowie Verwendung von
Hilfsmitteln, wie z. B. dem individuellen Stellen der Arzneimittel.
Die Wirksamkeit ist nur für die Dauer der Interventionen
dokumentiert.
Die Verbesserung der Einnahmetreue ist ein Forschungsgebiet mit
zunehmender Bedeutung für Morbidität und Kosten.
Maßnahmen zur Verbesserung der Einnahmetreue sind ähnlich
wichtig einzustufen wie die Erforschung neuer Wirkstoffe. Dennoch
fehlen insbesondere für das deutsche Gesundheitssystem
prospektive Studien mit klinischen Endpunkten, um evidenzbasierte Empfehlungen
entwickeln zu können. Hier sind gemeinsame Anstrengungen
von Ärzten und Apothekern erforderlich.
Abstract
Up to 50 % of patients with chronic diseases
do not take their medication regularly. Poor adherence to drug therapy
is associated with higher morbidity and mortality.
A selective literature search using the terms adherence, compliance,
concordance, persistence, medication management, and pharmaceutical
care was performed.
Evidence for improving adherence has been provided for the following
principles: individual counselling of patients and care givers,
medication management including simplifying dosing and use of combination
tablets as well as the use of individual unit doses, e. g.
blister cards. The effectiveness has only been shown for the duration
of the interventions.
The improvement of medication adherence represents an area of
research with high impact on outcomes and cost. Measures to improve
adherence may be as important as the development of novel therapies.
However, prospective clinical evaluations with clinical endpoints
are missing especially for the German health care system in order
to develop recommendations for clinical practice. Joint efforts
of physicians and pharmacists are needed.
Schlüsselwörter
Einnahmetreue - Therapietreue - Compliance - Pharmazeutische Betreuung - Medikationsmanagement
Keywords
adherence - compliance - concordance - medication management - pharmaceutical care
Literatur
-
1
Bangalore S, Kamalakkannan G, Parkar S, Messerli F H.
Fixed-dose combinations
improve medication compliance: a meta-analysis.
Am J Med.
2007;
120
713-719
-
2
Baroletti S, Dell’Orfano H.
Medication
adherence in cardiovascular disease.
Circulation.
2010;
121
1455-1458
-
3
Bates D W, Miller E B, Cullen D J. et al .
Patient risk factors for
adverse drug events in hospitalized patients. ADE Prevention Study
Group.
Arch Intern Med.
1999;
159
2553-2560
-
4
Claxton A J, Cramer J, Pierce C.
A systematic review of the associations between dose regimens
and medication compliance.
Clin Ther.
2001;
23
1296-1310
-
5
Cutler D M, Everett W.
Thinking outside the
pillbox-medication adherence as a priority for health care reform.
N Engl J Med.
2010;
362
1553-1555
-
6
DiMatteo M R, Lepper H S, Croghan T W.
Depression is a risk factor for noncompliance
with medical treatment: meta-analysis of the effects of anxiety
and depression on patient adherence.
Arch Intern Med.
2000;
160
2101-2107
-
7
Dormuth C R, Patrick A R, Shrank W H. et al .
Statin adherence and risk
of accidents: a cautionary tale.
Circulation.
2009;
119
2051-2057
-
8
Düsing R, Handrock R, Klebs S, Tousset E, Vrijens B.
Impact of supportive measures on drug adherence in patients
with essential hypertension treated with valsartan: the randomized,
open-label, parallel group study VALIDATE.
J Hypertens.
2009;
27
894-901
-
9
Fonarow G C, Abraham W T, Albert N M. et al .
Factors identified as precipitating
hospital admissions for heart failure and clinical outcomes: findings
from OPTIMIZE-HF.
Arch Intern Med.
2008;
168
847-854
-
10
Gehi A, Haas D, Pipkin S, Whooley M A.
Depression and medication adherence
in outpatients with coronary heart disease: findings from the Heart
and Soul Study.
Arch Intern Med.
2005;
165
2508-2513
-
11
Gehi A K, Ali S, Na B, Whooley M A.
Self-reported medication adherence
and cardiovascular events in patients with stable coronary heart
disease: the heart and soul study.
Arch Intern Med.
2007;
167
1798-1803
-
12
Glader E L, Sjolander M, Eriksson M, Lundberg M.
Persistent use of secondary
preventive drugs declines rapidly during the first 2 years after
stroke.
Stroke.
2010;
41
397-401
-
13
Granger B B, Swedberg K, Ekman I. et al .
Adherence to candesartan and placebo and
outcomes in chronic heart failure in the CHARM programme: double-blind,
randomised, controlled clinical trial.
Lancet.
2005;
366
2005-2011
-
14
Haynes R B, Ackloo E, Sahota N, McDonald H P, Yao X.
Interventions for enhancing medication adherence.
Cochrane
Database Syst Rev.
2008. CD000011;
-
15
Ho P M, Bryson C L, Rumsfeld J S.
Medication adherence: its importance in
cardiovascular outcomes.
Circulation.
2009;
119
3028-3035
-
16
Julius R J, Novitsky Jr M A, Dubin W R.
Medication adherence: a review of
the literature and implications for clinical practice.
J
Psychiatr Pract.
2009;
15
34-44
-
17
Kamal-Bahl S J, Burke T, Watson D, Wentworth C.
Discontinuation of lipid
modifying drugs among commercially insured United States patients
in recent clinical practice.
Am J Cardiol.
2007;
99
530-534
-
18
Kripalani S, Yao X, Haynes R B.
Interventions to enhance medication adherence in chronic medical
conditions: a systematic review.
Arch Intern Med.
2007;
167
540-550
-
19
Laufs U, Rettig-Ewen V, Bohm M.
Strategies to improve drug adherence.
Eur Heart J.
2011;
32
264-268
-
20
Lee J K, Grace K A, Taylor A J.
Effect of a pharmacy care program on medication
adherence and persistence, blood pressure, and low-density lipoprotein
cholesterol: a randomized controlled trial.
JAMA.
2006;
296
2563-2571
-
21
Murray M D, Young J, Hoke S. et
al .
Pharmacist intervention to improve medication adherence
in heart failure: a randomized trial.
Ann Intern Med.
2007;
146
714-725
-
22
Ogedegbe G, Chaplin W, Schoenthaler A. et al .
A practice-based trial of motivational
interviewing and adherence in hypertensive African Americans.
Am J Hypertens.
2008;
21
1137-1143
-
23
Paes A H, Bakker A, Soe-Agnie C J.
Impact of dosage frequency on patient compliance.
Diabetes
Care.
1997;
20
1512-1517
-
24
van Penning-Beest F J, Termorshuizen F, Goettsch W G, Klungel O H, Kastelein J J, Herings R M.
Adherence to evidence-based statin guidelines reduces
the risk of hospitalizations for acute myocardial infarction by
40 %: a cohort study.
Eur Heart J.
2007;
28
154-159
-
25
Rasmussen J N, Chong A, Alter D A.
Relationship between adherence to evidence-based pharmacotherapy
and long-term mortality after acute myocardial infarction.
JAMA.
2007;
297
177-186
-
26
Reddy K S.
The preventive polypill – much promise, insufficient
evidence.
N Engl J Med.
2007;
356
212
-
27
Rieckmann N, Gerin W, Kronish I M. et al .
Course of depressive symptoms and medication
adherence after acute coronary syndromes: an electronic medication
monitoring study.
J Am Coll Cardiol.
2006;
48
2218-2222
-
28
Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann A D.
Continuation of
statin treatment and all-cause mortality: a population-based cohort
study.
Arch Intern Med.
2009;
169
260-268
-
29
Simpson S H, Eurich D T, Majumdar S R. et al .
A meta-analysis of the association
between adherence to drug therapy and mortality.
BMJ.
2006;
333
15
-
30
Sokol M C, McGuigan K A, Verbrugge R R, Epstein R S.
Impact of medication adherence on hospitalization risk and healthcare
cost.
Med Care.
2005;
43
521-530
-
31 World Health Organization .Adherence to long-term therapies. Evidence for action. http://whqlibdoc.who.int/publications/2003/9 241 545 992.pdf 2003
-
32
Wu J Y, Leung W Y, Chang S. et al .
Effectiveness of telephone counselling
by a pharmacist in reducing mortality in patients receiving polypharmacy:
randomised controlled trial.
BMJ.
2006;
333
522-525
-
33
Yusuf S, Pais P, Afzal R. et
al .
Effects of a polypill (Polycap) on risk factors
in middle-aged individuals without cardiovascular disease (TIPS):
a phase II, double-blind, randomised trial.
Lancet.
2009;
373
1341-1351
Prof. Dr. med. Ulrich Laufs
Klinik für Innere Medizin III
Kardiologie,
Angiologie und Internistische Intensivmedizin
Universitätsklinikum
des Saarlandes
66421 Homburg/Saar
Phone: 06841/162-3436/-1331
Fax: 06841/162-1331
Email: ulrich@laufs.com